Nutra Pharma Corporation (OTCQB: NPHC), a
biotechnology company marketing
Pet Pain-Away? in the over-the-counter (OTC)
pain management market, announced today that the Company and their
products were featured in an interview aired last night on Miami's
NBC News affiliate (
NBC News has been featuring the use of natural products for the
treatment of a variety of ailments, commented Rik J Deitsch, CEO
of Nutra Pharma. For the most part, these reports have discussed
the use of marijuana. Nutra Pharma's
Nyloxin has been shown to be just as potent as opiate pain
relievers without the side effects caused by the use of opiates or
marijuana, he continued. The report focusses on Nyloxin and Pet
Pain-Away. These are clinically proven, legal and all-natural
products that are available today to deal with pain and
inflammation in people and their pets, he concluded.
The interview was conducted by Jamie Guirola with filming at
Nutra Pharma's laboratory facility and the reptile farm that houses
their cobras for venom production. Jamie, through his
interviews, learned about cobra venom and its use as a potent
pain-reliever (analgesic) and anti-inflammatory agent.
Nutra Pharma will announce further strategic business segment
actions over the coming weeks. The Company expects to address
Nyloxin chronic pain solutions for the Sports-Athletic
market as well as for Aging Individuals and Baby Boomers. Nutra
Pharma is also addressing chronic pain in pets, especially dogs and
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology
company specializing in the acquisition, licensing, and
commercialization of pharmaceutical products and technologies for
the management of neurological disorders, cancer, autoimmune, and
infectious diseases, including Multiple Sclerosis (MS), Human
Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain.
Additionally, the Company markets drug products for sale for the
treatment of pain under the brand
Pet Pain-Away?. For additional information about Nutra
This press release contains forward-looking statements. The
words or phrases would be, will allow, intends to, will
likely result, are expected to, will continue, is
anticipated, estimate, project, or similar expressions are
intended to identify forward-looking statements. Actual results
could differ materially from those projected in Nutra Pharma's
(the Company) business plan. The news piece on NBC News should
not be construed as an indication in any way whatsoever of the
future value of the Company's common stock or its financial value.
The Company's filings may be accessed at the SEC's Edgar system at
www.sec.gov. Statements made herein are as
of the date of this press release and should not be relied upon as
of any subsequent date. The Company cautions readers not to place
reliance on such statements. Unless otherwise required by
applicable law, we do not undertake, and we specifically disclaim
any obligation, to update any forward-looking statements to reflect
occurrences, developments, unanticipated events or circumstances
after the date of such statement.
Nutra Pharma Corp.
Nutra Pharma and Nyloxin Featured on NBC News-Miami appeared